F de la Portilla1,2, J J Segura-Sampedro3,4, M L Reyes-Díaz3, M V Maestre3, A M Cabrera3, R M Jimenez-Rodríguez3, J M Vázquez-Monchul3, J M Diaz-Pavón3, F J Padillo-Ruiz3. 1. Department of General and Digestive Surgery, Colorectal Surgery Unit, "Virgen del Rocío" University Hospital/IBiS/CSIC/University of Seville, Avda. Manuel Siurot s/n, 41013, Sevilla, Spain. fportilla@us.es. 2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD o Ciberehd), Instituto de Salud Carlos III, Madrid, Spain. fportilla@us.es. 3. Department of General and Digestive Surgery, Colorectal Surgery Unit, "Virgen del Rocío" University Hospital/IBiS/CSIC/University of Seville, Avda. Manuel Siurot s/n, 41013, Sevilla, Spain. 4. Department of General and Digestive Surgery, "Son Espases" University Hospital/IdISPa, Palma de Mallorca, Spain.
Abstract
PURPOSE: The aim of this paper is to evaluate to the safety, feasibility and efficacy of a novel treatment for transsphincteric cryptoglandular fistula: injection of autologous plasma rich in growth factors (PRGF) into the fistula tract accompanied by sealing using a fibrin plug created from the activated platelet-poor fraction of the same plasma. METHOD: This article is a prospective, phase II clinical trial. The procedure was externally audited. Thirty-six patients diagnosed with transsphincteric fistula-in-ano were included. All patients underwent follow-up examinations at 1 week and again at 3, 6 and 12 months after discharge. Main outcome measures safety (number of adverse events), feasibility and effectiveness of the treatment. RESULTS: A total of 36 patients received the study treatment, with the procedure found to be feasible in all patients. A total of seven adverse events (AE) related to the injected product or surgical procedure were identified in 4 of 36 patients. At the end of the follow-up period (12 months), 33.3% of patients (12/36) had achieved complete fistula healing and 11.1% of patients (4/36) had achieved partial healing. In total, this amounted to 44.4% of patients (16/36) being asymptomatic at final follow-up. In successfully healed patients, a gradual reduction in pain was observed, as measured using a Visual Analog Scale (VAS) (p = 0.0278). Compared to baseline, a significant improvement in Wexner score was seen in patients achieving total or partial healing of the fistula (p = 0.0195). CONCLUSIONS: The study treatment was safe and feasible, with apparently modest efficacy rates. Continence and pain improvement following treatment may be considered predictive factors for healing.
PURPOSE: The aim of this paper is to evaluate to the safety, feasibility and efficacy of a novel treatment for transsphincteric cryptoglandular fistula: injection of autologous plasma rich in growth factors (PRGF) into the fistula tract accompanied by sealing using a fibrin plug created from the activated platelet-poor fraction of the same plasma. METHOD: This article is a prospective, phase II clinical trial. The procedure was externally audited. Thirty-six patients diagnosed with transsphincteric fistula-in-ano were included. All patients underwent follow-up examinations at 1 week and again at 3, 6 and 12 months after discharge. Main outcome measures safety (number of adverse events), feasibility and effectiveness of the treatment. RESULTS: A total of 36 patients received the study treatment, with the procedure found to be feasible in all patients. A total of seven adverse events (AE) related to the injected product or surgical procedure were identified in 4 of 36 patients. At the end of the follow-up period (12 months), 33.3% of patients (12/36) had achieved complete fistula healing and 11.1% of patients (4/36) had achieved partial healing. In total, this amounted to 44.4% of patients (16/36) being asymptomatic at final follow-up. In successfully healed patients, a gradual reduction in pain was observed, as measured using a Visual Analog Scale (VAS) (p = 0.0278). Compared to baseline, a significant improvement in Wexner score was seen in patients achieving total or partial healing of the fistula (p = 0.0195). CONCLUSIONS: The study treatment was safe and feasible, with apparently modest efficacy rates. Continence and pain improvement following treatment may be considered predictive factors for healing.
Authors: Kevin W Göttgens; Wouter Vening; Stefan J van der Hagen; Wim G van Gemert; Reinier R Smeets; Laurents P Stassen; Cor G Baeten; Stephanie O Breukink Journal: Dis Colon Rectum Date: 2014-02 Impact factor: 4.585
Authors: F J Pérez Lara; A Moreno Serrano; J Ulecia Moreno; J Hernández Carmona; M Ferrer Marquez; L Romero Pérez; A del Rey Moreno; H Oliva Muñoz Journal: J Gastrointest Surg Date: 2014-11-25 Impact factor: 3.452
Authors: A Amato; C Bottini; P De Nardi; P Giamundo; A Lauretta; A Realis Luc; V Piloni Journal: Tech Coloproctol Date: 2020-01-23 Impact factor: 3.781